X-ZELL

X ZELL is a global pioneer in multiplexed immunostaining – a patented technology set to revolutionize cancer diagnostics by applying multiple diagnostic antibodies simultaneously to a single specimen. Our FDA and CE IVD registered next generation cytology platform was specifically designed for minimally invasive cytology samples and processes up to eight antibodies at once – maximizing diagnostic yield while cutting turnaround by over 90%. No complex preparation. No sample wastage. By combining multiplexing with cutting edge digital imaging, we help laboratories deliver faster, more patient friendly, and personalized care – ready for the digital age. In May 2025, we previewed our new Cryophore™ range, the world’s first standardized, expert vetted multiplexing panels for routine cytopathology, set to launch globally in Q4 2025. Headquartered in Singapore, X ZELL operates regional offices in Germany, Thailand, and the US to advance diagnostics and improve patient care worldwide.